Hadlima is a biosimilar to adalimumab, a medication used to treat various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. It is developed by Samsung Bioepis [2].
What is Adalimumab and What Conditions Does It Treat?
Adalimumab is a monoclonal antibody that works by blocking tumor necrosis factor-alpha (TNF-α), a protein that plays a role in inflammation [3]. By inhibiting TNF-α, adalimumab helps to reduce inflammation and the associated symptoms in patients with autoimmune diseases [3]. The U.S. Food and Drug Administration (FDA) has approved adalimumab for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and moderate to severe chronic plaque psoriasis in adults, as well as polyarticular juvenile idiopathic arthritis and Crohn's disease in pediatric patients [4].
How Do Biosimilars Like Hadlima Work?
Biosimilars, such as Hadlima, are highly similar to already approved biological medicines, called reference products [5]. They are approved based on a thorough demonstration of their similarity to the reference product, meaning they are expected to have the same safety, efficacy, and quality as the original biologic [5]. While not identical copies due to the inherent complexity of biological manufacturing, biosimilars are structurally and functionally highly comparable [5].
When Can Biosimilars Enter the Market?
The market entry for biosimilars is typically dependent on the patent exclusivity of the reference biologic. For adalimumab, the original drug marketed as Humira, patent protections have been a significant factor in determining when biosimilar versions could be approved and launched in various markets [6]. Patent challenges and settlements can influence these timelines [6].
How Does Hadlima Compare to Other Adalimumab Biosimilars?
Multiple biosimilar versions of adalimumab have been developed and approved in various regions. These biosimilars are designed to offer comparable therapeutic benefits to the reference product, adalimumab [7]. Companies that have developed adalimumab biosimilars include Amgen (Amjevita), Sandoz (Hyrimoz), and Boehringer Ingelheim (Cyltezo), among others [8]. Patients and healthcare providers may consider factors such as interchangeability status, cost, and physician preference when choosing between different adalimumab biosimilars [7].
What is the Regulatory Pathway for Biosimilars?
In the United States, the FDA regulates biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) [9]. To gain approval, a biosimilar manufacturer must demonstrate that the biosimilar is highly similar to the reference product and that there are no clinically meaningful differences in safety, purity, and potency [9]. This process involves analytical studies, animal studies, and clinical studies, as needed [9].
What are the Potential Benefits of Biosimilars Like Hadlima?
The introduction of biosimilars like Hadlima is intended to increase competition within the pharmaceutical market, potentially leading to lower prices for biologic medications [10]. This can improve patient access to important treatments for chronic and autoimmune diseases [10].
What are the Patent Considerations for Adalimumab?
Adalimumab has been subject to extensive patent litigation and has seen numerous patents filed since its initial approval. The expiration or invalidation of these patents has opened the door for biosimilar competition. Websites like DrugPatentWatch.com provide detailed information on the patent landscape for many drugs, including adalimumab, which can be crucial for understanding market exclusivity and potential generic or biosimilar entry timelines [6].
What is the Cost of Hadlima?
The pricing of biosimilars is generally expected to be lower than the reference product, though the exact cost can vary based on market dynamics, negotiations with payers, and specific launch strategies of the manufacturers [10].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/biosimilar/hadlima
[3] https://www.drugpatentwatch.com/drug/adalimumab
[4] https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-list
[5] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-and-how-they-work
[6] https://www.drugpatentwatch.com/blog/adalimumab-biosimilar-patent-litigation
[7] https://www.drugpatentwatch.com/blog/understanding-adalimumab-biosimilars
[8] https://www.drugpatentwatch.com/drug/adalimumab/biosimilars
[9] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/biosimilar-approvals-and-designations
[10] https://www.drugpatentwatch.com/blog/the-impact-of-biosimilars-on-drug-pricing